NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » SFDA approved  1  2  3  4  5  » 
found files: 153
AstraZeneca »17/02/2007 [Company watch]
AstraZeneca Wins 2nd Award for Investment in China

Following $134millions investment in a manufacturing plant at Wuxi in 2001, AZ have announced a further $35millions investment in the site. In May 2006 AZ announced its intention to invest $100millions in R & D in China....   more»


Novo Nordisk »05/03/2007 [Company watch]
Novo Nordisk and Chinese Academy of Science establish Research Foundation

Novo Nordisk have committed $2million to co-fund research activities of mutual interest - diabetes and biopharmaceuticals....   more»


Charles River »23/03/2007 [Company watch]
Charles River commits to large expansion programme in Shanghai

Charles River Laboratories International, Inc. (NYSE:CRL) announced today the expansion of its global footprint in Asia as part of its strategy to support customers' research and development efforts in this rapidly growing market....   more»


AstraZeneca »23/03/2007 [Company watch]
AStraZeneca name site for lab expansion plan

AStrazeneca confirm site for their $100Million R & D expansion in China as the Zhangjiang Hi-Tech park in Shanghai with completion due in mid 2007. Recruitrment of scientists is already underway. The Innovation Center China will open in mid-2007 before the establishment of a permanent site that officials are still looking for....   more»


NCCSED »06/03/2007 [Industry news]
Frontier links with NCCSED (CRO) in China

US based Frontier Biosciences has signed agreement with National Chengdu Centre for Safety Evaluation of Drugs - a full service pre-clinical CRO regarded as one of the best in China - established by West China Hospital of the Sichuan University...   more»


Wuxi Pharma Tech »07/04/2007 [Industry news]
WuXi PharmaTech Sets Up Life Science and Chemistry Award

WuXi PharmaTech, China's leading provider of pharmaceutical outsourcing services is pleased to announce the establishment of the "WuXi PharmaTech Life Science and Chemistry Award"; worth one million RMB. The award will honor individuals and groups who make a significant contribution to the fields of life science and chemistry in China....   more»


AstraZeneca »24/04/2007 [Company watch]
AStra Zeneca are advertising for :TRANSLATIONAL SCIENTIST for pre-clinical development in cancer research

AStra Zeneca are seeking an experienced scientist to lead pre clinical cancer trials team in the Shanghai Innovation Centre - full job advert below, to be fully operational by 2009...   more»


Novo Nordisk »03/05/2007 [Company watch]
Novo Nordisk will continue to exploit the emerging importance of China in pharma research by establishing a new diabetes research foundation there.

UPDATE: The Danish pharma company is setting up a joint science research foundation with the Chinese Academy of Science (CAS). The collaboration will concentrate on diabetes and biopharmaceuticals research, including related fields and technologies such as protein chemistry, immunology, inflammation, toxicology, oncology and drug delivery....   more»


Simcere Pharmaceutical Group »19/04/2007 [Finance]
Simcere Pharmaceutical Group Announces Pricing of Initial Public Offering on NYSE

Simcere Pharmaceutical Group, a leading manufacturer and supplier of branded generic pharmaceuticals in the rapidly growing China market, announced today that its initial public offering of 15,625,000 American Depositary Shares (ADSs), each representing two ordinary shares, was priced at an initial public offering price of $14.50 per ADS. The ADSs will begin trading on the New York Stock Exchange on April 20, 2007 under the symbol ''SCR.''...   more»


Covance »30/04/2007 [Company watch]
First Quarter 07 Results

copy of results...   more»


Charles River »08/05/2007 [Company watch]
Charles River announces 1st Quarter 2007 results

see full report...   more»


Charles River »24/04/2007 [Company watch]
Charles River Laboratories Appoints Cheri Walker, Ph.D. as Corporate Senior Vice President, Corporate Development

Charles River Laboratories International, Inc. (NYSE: CRL) announced today the appointment of Cheri Walker, Ph.D. to the role of Corporate Senior Vice President, Corporate Development, effective April 24, 2007. Dr. Walker will be responsible for the Company's global corporate development function, directing all aspects of our merger, acquisition and strategic joint venture activities. She will also participate as an integral member in the strategic planning process of the Company. Prior to joining Charles River, Dr. Walker was Vice President, Mergers and Acquisitions for QIAGEN Sciences where she oversaw the corporate development of QIAGEN's North American life sciences tools and molecular diagnostics businesses. Previously, Dr. Walker held senior corporate development and operational positions at Invitrogen where she successfully executed acquisition and licensing transactions. James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories noted, "We are delighted to have Cheri join the Charles River team. Her depth of experience in life science transactions adds greater strength to our management team." Dr. Walker commented, "I have followed the growth of Charles River for several years and am very excited to be joining a dynamic and expanding company. Corporate Development will play an integral role in this growth and I am looking forward to being part of the team." Dr. Walker holds a doctorate in Human and Molecular Genetics from Baylor College of Medicine and a bachelor's degree in Biology from Swarthmore College....   more»


Simcere Pharmaceutical Group »03/06/2007 [Industry news]
Simcere Pharmaceutical Group is looking to build its future on research

Flush with cash from its US IPO, Simcere Pharmaceutical Group is looking to build its future on research. Late last month, Simcere weighed in with the largest IPO on the New York Stock Exchange for an Asian pharmaceutical company, raising 261 mln usd. Now it plans to put some of that money to work. 'We need to consider both the long-term and the short-term,' said Jinsheng Ren, chairman and CEO. 'Pharmaceutical technology can really set companies apart in China and that is why we say R & D is our focus.' "THIS HIGHLY RESPECTED COMPANY COULD BE A GOOD PARTNER FOR HLS"...   more»


Charles River »10/06/2007 [Company watch]
Charles River Laboratories (CRL) will begin operating in China, establishing a joint venture with Shanghai BioExplorer Co., Ltd,

Charles River Laboratories (CRL) will begin operating in China, establishing a joint venture with Shanghai BioExplorer Co., Ltd, a Shanghai company that, like Charles River, provides pre-clinical CRO (Contract Research Organization) services. As one of the top two U.S. CROs, the menu of Charles River offerings are somewhat larger than BioExplorer's, although these will be expanded to meet the stated goal of supporting its customers’ needs, from drug discovery through proof of concept on a global basis....   more»


TOP NEWS
Wuxi Pharma Tech
»06/07/2007 [Company watch]
IPO for WuXi PharmaTech?

Outsourcing powerhouse WuXi PharmaTech is rumored to be on the verge of announcing its IPO. The Shanghai-based company has been a huge success story right from the outset of its 2001 startup, now boasting 1,550 scientific staff members and over 2,000 employees overall....   more»


Wuxi Pharma Tech »25/07/2007 [Company watch]
Wuxi Pharma TechPlans $120Million US public offering

WuXi PharmaTech, the biggest Chinese contract research organisation (CRO), has put an end to weeks of speculation by officially announcing it plans an initial public offering (IPO) on the New York Stock Exchange....   more»


Wuxi Pharma Tech »10/08/2007 [Company watch]
Wuxi Raises $185Million from IPO

The NYSE listing of the Chinese drug research company receives substantial demand, enabling it to price 8% higher than the top of the range....   more»


Wuxi Pharma Tech »19/08/2007 [Company watch]
China\'s WuXi PharmaTech adds 3 senior level positions to management

China\'s WuXi PharmaTech, a New York Stock Exchange-listed provider of pharmaceutical research and development outsourcing services, said it has added three senior level positions to its management, namely executive vice president of operations, vice president of toxicology and vice president of finance....   more»


Covance »30/08/2007 [Company watch]
Covance Advances on its Shanghai Lab

Interestingly, Covance said its increased presence in China was due to the higher level of pharmaceutical activity there. Usually, companies invest in China because of some combination of low costs or interest in the country’s growing market for drugs. Because China is expected to be the fifth largest market in the world by 2010 – just three years away – Covance felt the need to be a part of this vital area of pharmaceutical enterprise, to be close to the action. Covance is a $4.5 billion contract research organization with revenues of $1.5 billion annually. During the last week, we noted that big pharma was choosing to build new facilities in China rather than India (see story). Then Novartis (NVS), which just last year announced its intention to make major investments in both countries, reneged on its commitment to India (see story). The cause underlying both stories was poor patent protection in India. For Novartis, the decision was made after the company lost a patent infringement suit against a generic version of leukemia drug Gleevec. Also in the news last week, Beijing Med-Pharm (BJGP) raised $31 million that will allow the company to continue its acquisitive ways (see story), China Shenghuo (KUN) reported much improved Q2 results (see story), Optimer Pharma (OPTR) entered talks with C&O Pharma (of Taiwan, Hong Kong and China) to discuss future collaborations (see story), and China decided to allow its citizens the right to invest in Hong Kong-listed stocks (see story). The change may have the effect of making Hong Kong a more-preferred exchange for biomedical enterprises that are planning their IPOs....   more»


Wuxi Pharma Tech »31/08/2007 [Finance]
Wuxi shares have risen 91% since Aug 9th IPO

Just thought you'd be interested - the remaining share index fell by 2% over the same period. Ist quarter earnings this year Wuxi was up 900% on the same period last year...   more»

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.